Mitochondrial medicine for neurodegenerative diseases

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 5, 2010, Pages 560-572

  Du, Heng ^a   Yan, Shirley ShiDu ^a  

^a Columbia University ^*  (United States)

Author keywords

Mitochondria; Mitochondrial medicine; Mitochondrial pathology; Neurodegeneration; Neurodegenerative diseases

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; CHOLEST 4 EN 3 ONE; CYCLOSPORIN A; FLAVONOID; FREE RADICAL; GINSENOSIDE; GLUTATHIONE; GREEN TEA EXTRACT; ISOFLAVONE DERIVATIVE; MITOCHONDRIAL DNA; MITOQ; MITOVIT E; PEPTIDE; PEPTIDE NUCLEIC ACID; POLYPHENOL; QUINONE DERIVATIVE; SANGLIFEHRIN A; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SS 02; SS 31; SS PEPTIDE; TACROLIMUS; TRANSCRIPTION FACTOR; TRU 19622; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; MEDICINE; MITOCHONDRIAL MEDICINE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; SHORT SURVEY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CALCIUM SIGNALING; DNA DAMAGE; DNA, MITOCHONDRIAL; DRUG DELIVERY SYSTEMS; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; GENE THERAPY; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 77649184822     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.01.004     Document Type: Short Survey

References (240)

1. Abou-Sleiman P.M., Muqit M.M., McDonald N.Q., Yang Y.X., Gandhi S., Healy D.G., et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 60 (2006) 414-419
2. Adlam V.J., Harrison J.C., Porteous C.M., James A.M., Smith R.A., Murphy M.P., et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19 (2005) 1088-1095
3. Alam M., and Schmidt W.J. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease. Physiol Behav 83 (2004) 395-400
4. Albers D.S., Augood S.J., Park L.C., Browne S.E., Martin D.M., Adamson J., et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 74 (2000) 878-881
5. Albers D.S., and Beal M.F. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 40 (2002) 559-564
6. Albers D.S., Swerdlow R.H., Manfredi G., Gajewski C., Yang L., Parker Jr. W.D., et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 168 (2001) 196-198
7. Almeida S., Sarmento-Ribeiro A.B., Januario C., Rego A.C., and Oliveira C.R. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochem Biophys Res Commun 374 (2008) 599-603
8. Aoyama K., Matsubara K., and Kobayashi S. Aging and oxidative stress in progressive supranuclear palsy. Eur J Neurol 13 (2006) 89-92
9. Arenas J., Campos Y., Ribacoba R., Martin M.A., Rubio J.C., Ablanedo P., et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 43 (1998) 397-400
10. Ascherio A., Weisskopf M.G., O'Reilly E.J., Jacobs E.J., McCullough M.L., Calle E.E., et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol 57 (2005) 104-110
11. Bacman S.R., Williams S.L., Hernandez D., and Moraes C.T. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther 14 (2007) 1309-1318
12. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
13. Banerjee R., Starkov A.A., Beal M.F., and Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792 (2009) 651-663
14. Bayona-Bafaluy M.P., Blits B., Battersby B.J., Shoubridge E.A., and Moraes C.T. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci USA 102 (2005) 14392-14397
15. Beal M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 36 (2002) 455-460
16. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53 Suppl. 3 (2003) S39-S47
17. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58 (2005) 495-505
18. Beal M.F., Matthews R.T., Tieleman A., and Shults C.W. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783 (1998) 109-114
19. Becker T., Gebert M., Pfanner N., and van der Laan M. Biogenesis of mitochondrial membrane proteins. Curr Opin Cell Biol 21 (2009) 484-493
20. Begley J.G., Duan W., Chan S., Duff K., and Mattson M.P. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem 72 (1999) 1030-1039
21. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17 (2006) 1652-1663
22. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 125 (1994) 95-101
23. Bohr V.A. Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells. Free Radic Biol Med 32 (2002) 804-812
24. Boothby L.A., and Doering P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39 (2005) 2073-2080
25. Bordet T., Buisson B., Michaud M., Drouot C., Galea P., Delaage P., et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322 (2007) 709-720
26. Borlongan C.V., Stahl C.E., Keep M.F., Elmer E., and Watanabe S. Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. Neurosci Lett 279 (2000) 73-76
27. Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., and Sheu S.S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 287 (2004) C817-C833
28. Browne S.E. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann NY Acad Sci 1147 (2008) 358-382
29. Brustovetsky N., Brustovetsky T., Purl K.J., Capano M., Crompton M., and Dubinsky J.M. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci 23 (2003) 4858-4867
30. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36 (2002) 1307-1313
31. Butterfield D.A., Perluigi M., and Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545 (2006) 39-50
32. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., et al. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21 (2001) 5110-5120
33. Calderon Guzman D., Trujillo Jimenez F., Hernandez Garcia E., and Juarez Olguin H. Assessment of antioxidant effect of 2,5-dihydroxybenzoic acid and vitamin A in brains of rats with induced hyperoxia. Neurochem Res 32 (2007) 1036-1040
34. Cardoso S.M., Santana I., Swerdlow R.H., and Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89 (2004) 1417-1426
35. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19 (2005) 2040-2041
36. Cassarino D.S., Swerdlow R.H., Parks J.K., Parker Jr. W.D., and Bennett Jr. J.P. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 248 (1998) 168-173
37. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 (2006) 1241-1252
38. Chan W.H., and Yu J.S. Inhibition of UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermal carcinoma A431 cells by genistein. J Cell Biochem 78 (2000) 73-84
39. Chaturvedi R.K., and Beal M.F. Mitochondrial approaches for neuroprotection. Ann NY Acad Sci 1147 (2008) 395-412
40. Chen Z.Y., He C.Y., Ehrhardt A., and Kay M.A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8 (2003) 495-500
41. Chinnery P.F., Taylor R.W., Diekert K., Lill R., Turnbull D.M., and Lightowlers R.N. Peptide nucleic acid delivery to human mitochondria. Gene Ther 6 (1999) 1919-1928
42. Chirichigno J.W., Manfredi G., Beal M.F., and Albers D.S. Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Res 951 (2002) 31-35
43. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324 (2009) 102-105
44. Cho J., Won K., Wu D., Soong Y., Liu S., Szeto H.H., et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis 18 (2007) 215-220
45. Cleren C., Yang L., Lorenzo B., Calingasan N.Y., Schomer A., Sireci A., et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104 (2008) 1613-1621
46. Conte V., Uryu K., Fujimoto S., Yao Y., Rokach J., Longhi L., et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 90 (2004) 758-764
47. Cortopassi G., Danielson S., Alemi M., Zhan S.S., Tong W., Carelli V., et al. Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts. Mitochondrion 6 (2006) 161-175
48. Coskun P.E., Beal M.F., and Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101 (2004) 10726-10731
49. Costa C., Belcastro V., Tozzi A., Di Filippo M., Tantucci M., Siliquini S., et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28 (2008) 8040-8052
50. Dal Canto M.C., and Gurney M.E. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 676 (1995) 25-40
51. 2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem 96 (2006) 1349-1361
52. de Magalhaes J.P. Human disease-associated mitochondrial mutations fixed in nonhuman primates. J Mol Evol 61 (2005) 491-497
53. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 9-18
54. Dhanasekaran A., Kotamraju S., Kalivendi S.V., Matsunaga T., Shang T., Keszler A., et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 279 (2004) 37575-37587
55. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14 (2008) 1097-1105
56. Du H., Guo L., Zhang W., Rydzewska M., and Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging April (2009) [Epub ahead of print]
57. Du H., and Yan S.S. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta 1802 January (1) (2010) 198-204
58. Dupuis L., Gonzalez de Aguilar J.L., Oudart H., de Tapia M., Barbeito L., and Loeffler J.P. Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Neurodegener Dis 1 (2004) 245-254
59. Echaniz-Laguna A., Zoll J., Ponsot E., N'Guessan B., Tranchant C., Loeffler J.P., et al. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp Neurol 198 (2006) 25-30
60. Ellouze S., Augustin S., Bouaita A., Bonnet C., Simonutti M., Forster V., et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 83 (2008) 373-387
61. Esteves A.R., Domingues A.F., Ferreira I.L., Januario C., Swerdlow R.H., Oliveira C.R., et al. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8 (2008) 219-228
62. Etminan M., Gill S.S., and Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 4 (2005) 362-365
63. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 Suppl. (1992) S128-S132
64. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32 (1992) 804-812
65. Fall C.P., and Bennett Jr. J.P. MPP+ induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid. Brain Res 811 (1998) 143-146
66. Faust K., Gehrke S., Yang Y., Yang L., Beal F., and Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci 10 (2009) 109
67. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., and Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27 (2007) 13614-13623
68. Ferrante K.L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65 (2005) 1834-1836
69. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (2002) 1592-1599
70. Flierl A., Jackson C., Cottrell B., Murdock D., Seibel P., and Wallace D.C. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol Ther 7 (2003) 550-557
71. Fontaine M.A., Geddes J.W., Banks A., and Butterfield D.A. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 75 (2000) 1709-1715
72. Forte M., Gold B.G., Marracci G., Chaudhary P., Basso E., Johnsen D., et al. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci USA 104 (2007) 7558-7563
73. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33 (2009) 627-638
74. 2+ in transgenic Huntington disease rats. J Biol Chem 283 (2008) 30715-30724
75. Gold B.G., Voda J., Yu X., McKeon G., and Bourdette D.N. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J Neurosci Res 77 (2004) 367-377
76. Gordeeva A.V., Zvyagilskaya R.A., and Labas Y.A. Cross-talk between reactive oxygen species and calcium in living cells. Biochemistry (Mosc) 68 (2003) 1077-1080
77. Graham D., Huynh N.N., Hamilton C.A., Beattie E., Smith R.A., Cocheme H.M., et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54 (2009) 322-328
78. Green P.S., Gridley K.E., and Simpkins J.W. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218 (1996) 165-168
79. Grivennikova V.G., and Vinogradov A.D. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 1757 (2006) 553-561
80. Gu G., Reyes P.E., Golden G.T., Woltjer R.L., Hulette C., Montine T.J., et al. Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 61 (2002) 634-639
81. Gu M., Cooper J.M., Taanman J.W., and Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44 (1998) 177-186
82. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., and Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39 (1996) 385-389
83. Guo S., Bezard E., and Zhao B. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic Biol Med 39 (2005) 682-695
84. Gurel A., Coskun O., Armutcu F., Kanter M., and Ozen O.A. Vitamin E against oxidative damage caused by formaldehyde in frontal cortex and hippocampus: biochemical and histological studies. J Chem Neuroanat 29 (2005) 173-178
85. Gutzmann H., and Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54 (1998) 301-310
86. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37 (1995) 714-722
87. Haas R.H., Parikh S., Falk M.J., Saneto R.P., Wolf N.I., Darin N., et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 120 (2007) 1326-1333
88. Halestrap A.P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 34 (2006) 232-237
89. Halestrap A.P., Griffiths E.J., and Connern C.P. Mitochondrial calcium handling and oxidative stress. Biochem Soc Trans 21 (1993) 353-358
90. Halestrap A.P., Woodfield K.Y., and Connern C.P. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 272 (1997) 3346-3354
91. Hanagasi H.A., Ayribas D., Baysal K., and Emre M. Mitochondrial complex I and II/III, and IV activities in familial and sporadic Parkinson's disease. Int J Neurosci 115 (2005) 479-493
92. Harrison F.E., Hosseini A.H., McDonald M.P., and May J.M. Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol Biochem Behav 93 (2009) 443-450
93. Hayashi Y., Yoshida M., Yamato M., Ide T., Wu Z., Ochi-Shindou M., et al. Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice. J Neurosci 28 (2008) 8624-8634
94. Hervias I., Beal M.F., and Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33 (2006) 598-608
95. Higgins C.M., Jung C., and Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 4 (2003) 16
96. Hirano M., Nishigaki Y., and Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist 10 (2004) 8-17
97. Hong W.K., Han E.H., Kim D.G., Ahn J.Y., Park J.S., and Han B.G. Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. Neurochem Res 32 (2007) 1483-1488
98. Hollenbeck P.J., and Saxton W.M.J. The axonal transport of mitochondria. Cell Sci. 118 December (1) (2005) 5411-5419
99. Horvath T.L., Diano S., Leranth C., Garcia-Segura L.M., Cowley M.A., Shanabrough M., et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 144 (2003) 2757-2760
100. Howell N., Elson J.L., Chinnery P.F., and Turnbull D.M. mtDNA mutations and common neurodegenerative disorders. Trends Genet 21 (2005) 583-586
101. Hurt E.C., Muller U., and Schatz G. The first twelve amino acids of a yeast mitochondrial outer membrane protein can direct a nuclear-coded cytochrome oxidase subunit to the mitochondrial inner membrane. EMBO J 4 (1985) 3509-3518
102. Hutchin T.P., Heath P.R., Pearson R.C., and Sinclair A.J. Mitochondrial DNA mutations in Alzheimer's disease. Biochem Biophys Res Commun 241 (1997) 221-225
103. Ishige K., Schubert D., and Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30 (2001) 433-446
104. Jacobs H.T., Fernandez-Ayala D.J., Manjiry S., Kemppainen E., Toivonen J.M., and O'Dell K.M. Mitochondrial disease in flies. Biochim Biophys Acta 1659 (2004) 190-196
105. Jaiswal M.K., Zech W.D., Goos M., Leutbecher C., Ferri A., Zippelius A., et al. Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci 10 (2009) 64
106. James A.M., Sharpley M.S., Manas A.R., Frerman F.E., Hirst J., Smith R.A., et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem 282 (2007) 14708-14718
107. Jauslin M.L., Meier T., Smith R.A., and Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17 (2003) 1972-1974
108. Kang H.C., Kwon J.W., Lee Y.M., Kim H.D., Lee H.J., and Hahn S.H. Nonspecific mitochondrial disease with epilepsy in children: diagnostic approaches and epileptic phenotypes. Childs Nerv Syst 23 (2007) 1301-1307
109. Kantrow S.P., Tatro L.G., and Piantadosi C.A. Oxidative stress and adenine nucleotide control of mitochondrial permeability transition. Free Radic Biol Med 28 (2000) 251-260
110. Kasiviswanathan R., Longley M.J., Chan S.S., and Copeland W.C. Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication. J Biol Chem 284 (2009) 19501-19510
111. Kasparova S., Sumbalova Z., Bystricky P., Kucharska J., Liptaj T., Mlynarik V., et al. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int 48 (2006) 93-99
112. Keep M., Elmer E., Fong K.S., and Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res 894 (2001) 327-331
113. Kim S.H., Vlkolinsky R., Cairns N., and Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 57 (2000) 1810-1816
114. Kirkinezos I.G., Hernandez D., Bradley W.G., and Moraes C.T. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem 88 (2004) 821-826
115. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59 (1992) 776-779
116. Kontush A., Mann U., Arlt S., Ujeyl A., Luhrs C., Muller-Thomsen T., et al. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31 (2001) 345-354
117. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 19 (2000) 618-622
118. Kruman I.I., Pedersen W.A., Springer J.E., and Mattson M.P. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 160 (1999) 28-39
119. Kumar P., and Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res 63 (2009) 302-314
120. Kurzer M.S., and Xu X. Dietary phytoestrogens. Annu Rev Nutr 17 (1997) 353-381
121. Lazarou M., Thorburn D.R., Ryan M.T., and McKenzie M. Assembly of mitochondrial complex I and defects in disease. Biochim Biophys Acta 1793 (2009) 78-88
122. Leo S., Szabadkai G., and Rizzuto R. The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle. Ann NY Acad Sci 1147 (2008) 264-274
123. Leung A.W., and Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 1777 (2008) 946-952
124. Levites Y., Weinreb O., Maor G., Youdim M.B., and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78 (2001) 1073-1082
125. Li Z., Okamoto K., Hayashi Y., and Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 119 6 (2004) 873-887
126. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., et al. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 283 (2008) 5780-5789
127. Lim K.M., Kim H.H., Bae O.N., Noh J.Y., Kim K.Y., Kim S.H., et al. Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: evidence for the reduced platelet activities in Parkinson's disease. Platelets 20 (2009) 163-170
128. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006) 787-795
129. Littarru G.P., and Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 37 (2007) 31-37
130. Liu J., and Ames B.N. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 8 (2005) 67-89
131. Liu Y., Fiskum G., and Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 80 (2002) 780-787
132. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., and Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 39 (1996) 89-94
133. Longnecker M.P., Kamel F., Umbach D.M., Munsat T.L., Shefner J.M., Lansdell L.W., et al. Dietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosis. Neuroepidemiology 19 (2000) 210-216
134. Luchowska E., Luchowski P., Wielosz M., Turski W.A., and Urbanska E.M. FK506 attenuates 1-methyl-4-phenylpyridinium- and 3-nitropropionic acid-evoked inhibition of kynurenic acid synthesis in rat cortical slices. Acta Neurobiol Exp (Wars) 63 (2003) 101-108
135. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60 (2003) 203-208
136. Luft R., Ikkos D., Palmieri G., Ernster L., and Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 41 (1962) 1776-1804
137. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
138. Marella M., Seo B.B., Nakamaru-Ogiso E., Greenamyre J.T., Matsuno-Yagi A., and Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One 3 (2008) e1433
139. Martin-Kleiner I., Gabrilovac J., Bradvica M., Vidovic T., Cerovski B., Fumic K., et al. Leber's hereditary optic neuroretinopathy (LHON) associated with mitochondrial DNA point mutation G11778A in two Croatian families. Coll Antropol 30 (2006) 171-174
140. Martin L.J., Gertz B., Pan Y., Price A.C., Molkentin J.D., and Chang Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp Neurol 218 (2009) 333-346
141. Matthews R.T., Yang L., Browne S., Baik M., and Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95 (1998) 8892-8897
142. Mattiazzi M., D'Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Beal M.F., et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 277 (2002) 29626-29633
143. Mattson M.P. Mitochondrial regulation of neuronal plasticity. Neurochem Res. 32 (2007) 707-715
144. Mattson M.P., Partin J., and Begley J.G. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 807 (1998) 167-176
145. Mattson M.P., Rydel R.E., Lieberburg I., and Smith-Swintosky V.L. Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Ann NY Acad Sci 679 (1993) 1-21
146. McFarland R., Taylor R.W., and Turnbull D.M. The neurology of mitochondrial DNA disease. Lancet Neurol 1 (2002) 343-351
147. McFarland R., Taylor R.W., and Turnbull D.M. Mitochondrial disease-its impact, etiology, and pathology. Curr Top Dev Biol 77 (2007) 113-155
148. McIntosh L.J., Trush M.A., and Troncoso J.C. Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 23 (1997) 183-190
149. McKenzie M., Liolitsa D., and Hanna M.G. Mitochondrial disease: mutations and mechanisms. Neurochem Res 29 (2004) 589-600
150. Milakovic T., Quintanilla R.A., and Johnson G.V. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 281 (2006) 34785-34795
151. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005) 37-46
152. 2+ release. J Biol Chem 280 (2005) 715-721
153. Mohebbi N., Mihailova M., and Wagner C.A. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol 297 (2009) F499-F509
154. Morava E., van den Heuvel L., Hol F., de Vries M.C., Hogeveen M., Rodenburg R.J., et al. Mitochondrial disease criteria: diagnostic applications in children. Neurology 67 (2006) 1823-1826
155. Moreira P.I., Santos M.S., Sena C., Nunes E., Seica R., and Oliveira C.R. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 196 (2005) 112-119
156. Morris R.L., and Hollenbeck P.J. Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons. J Cell Biol 131 (1995) 1315-1326
157. Muller F.L., Liu Y., and Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279 (2004) 49064-49073
158. Murata T., Ohtsuka C., and Terayama Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic Res 42 (2008) 221-225
159. Muratovska A., Lightowlers R.N., Taylor R.W., Wilce J.A., and Murphy M.P. Targeting large molecules to mitochondria. Adv Drug Deliv Rev 49 (2001) 189-198
160. Muravchick S. Clinical implications of mitochondrial disease. Adv Drug Deliv Rev 60 (2008) 1553-1560
161. Murphy J.R. Protein engineering and design for drug delivery. Curr Opin Struct Biol 6 (1996) 541-545
162. Murphy M.P. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 1777 (2008) 1028-1031
163. Murphy M.P., and Smith R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 41 (2000) 235-250
164. Mutisya E.M., Bowling A.C., and Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63 (1994) 2179-2184
165. Naderi J., Somayajulu-Nitu M., Mukerji A., Sharda P., Sikorska M., Borowy-Borowski H., et al. Water-soluble formulation of Coenzyme Q10 inhibits Bax-induced destabilization of mitochondria in mammalian cells. Apoptosis 11 (2006) 1359-1369
166. Nanjo F., Goto K., Seto R., Suzuki M., Sakai M., and Hara Y. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21 (1996) 895-902
167. Nelson L.M., Matkin C., Longstreth Jr. W.T., and McGuire V. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am J Epidemiol 151 (2000) 164-173
168. Noorda G., Hermans-Peters M., Smeitink J., van Achterberg T., Kemps H., Goverde W., et al. Mitochondrial disease: needs and problems of children, their parents and family. A systematic review and pilot study into the need for information of parents during the diagnostic phase. J Inherit Metab Dis 30 (2007) 333-340
169. Onyango I.G., Lu J., Rodova M., Lezi E., Crafter A.B., and Swerdlow R.H. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta. 1802 January (1) (2010) 228-234
170. Panickar K.S., Polansky M.M., and Anderson R.A. Green tea polyphenols attenuate glial swelling and mitochondrial dysfunction following oxygen-glucose deprivation in cultures. Nutr Neurosci 12 (2009) 105-113
171. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem 269 (2005) 143-152
172. Paraskevas G.P., Kapaki E., Libitaki G., Zournas C., Segditsa I., and Papageorgiou C. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand 96 (1997) 88-90
173. Park J.S., Li Y.F., and Bai Y. Yeast NDI1 improves oxidative phosphorylation capacity and increases protection against oxidative stress and cell death in cells carrying a Leber's hereditary optic neuropathy mutation. Biochim Biophys Acta 1772 (2007) 533-542
174. Petersen A., Castilho R.F., Hansson O., Wieloch T., and Brundin P. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res 857 (2000) 20-29
175. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
176. Petri S., Kiaei M., Damiano M., Hiller A., Wille E., Manfredi G., et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98 (2006) 1141-1148
177. Pham D.Q., and Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother 39 (2005) 2065-2072
178. Polidori M.C., Mecocci P., Browne S.E., Senin U., and Beal M.F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 272 (1999) 53-56
179. Pons R., and De Vivo D.C. Mitochondrial disease. Curr Treat Options Neurol 3 (2001) 271-288
180. Quintanilla R.A., and Johnson G.V. Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Res Bull 80 October (4-5) (2009) 242-247
181. Reddy P.H. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromol Med 10 (2008) 291-315
182. Reddy P.H., and Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14 (2008) 45-53
183. Ren Y., Xu H.W., Davey F., Taylor M., Aiton J., Coote P., et al. Endophilin I expression is increased in the brains of Alzheimer disease patients. J Biol Chem 283 (2008) 5685-5691
184. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25 (2005) 8807-8814
185. Richter G., Sonnenschein A., Grunewald T., Reichmann H., and Janetzky B. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 109 (2002) 721-729
186. Rodriguez-Cuenca S., Cocheme H.M., Logan A., Abakumova I., Prime T.A., Rose C., et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 48 (2010) 161-172
187. Rosenstock T.R., Carvalho A.C., Jurkiewicz A., Frussa-Filho R., and Smaili S.S. Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid. J Neurochem 88 (2004) 1220-1228
188. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 (1997) 1216-1222
189. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1366 (1998) 225-233
190. Senin U., Parnetti L., Barbagallo-Sangiorgi G., Bartorelli L., Bocola V., Capurso A., et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15 (1992) 249-260
191. Setkowicz Z., Caryk M., Szafraniec M., Mudzinska A., and Janeczko K. Tacrolimus (FK506) and cyclosporin A reduce macrophage recruitment to the rat brain injured at perinatal and early postnatal periods. Neurol Res 31 December (10) (2009) 1060-1067
192. Sheehan J.P., Swerdlow R.H., Miller S.W., Davis R.E., Parks J.K., Parker W.D., et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 17 (1997) 4612-4622
193. Sheehan J.P., Swerdlow R.H., Parker W.D., Miller S.W., Davis R.E., and Tuttle J.B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 68 (1997) 1221-1233
194. Shoffner J.M., Brown M.D., Torroni A., Lott M.T., Cabell M.F., Mirra S.S., et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17 (1993) 171-184
195. Shults C.W., Flint Beal M., Song D., and Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 188 (2004) 491-494
196. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
197. Siklos L., and Kuhnt U. Calcium accumulation by dendritic mitochondria declines along the apical dendrites of pyramidal neurons in area CA1 of guinea pig hippocampal slices. Neurosci Lett 173 (1994) 131-134
198. Siler-Marsiglio K.I., Pan Q., Paiva M., Madorsky I., Khurana N.C., and Heaton M.B. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res 1052 (2005) 202-211
199. Sim C.H., Lio D.S., Mok S.S., Masters C.L., Hill A.F., Culvenor J.G., et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15 (2006) 3251-3262
200. Smith R.A., Porteous C.M., Coulter C.V., and Murphy M.P. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 263 (1999) 709-716
201. Stuart J.A., Hashiguchi K., Wilson III D.M., Copeland W.C., Souza-Pinto N.C., and Bohr V.A. DNA base excision repair activities and pathway function in mitochondrial and cellular lysates from cells lacking mitochondrial DNA. Nucleic Acids Res 32 (2004) 2181-2192
202. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18 (2004) 323-325
203. Supinski G.S., Murphy M.P., and Callahan L.A. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 297 (2009) R1095-R1102
204. Surh Y.J., Lee J.Y., Choi K.J., and Ko S.R. Effects of selected ginsenosides on phorbol ester-induced expression of cyclooxygenase-2 and activation of NF-kappaB and ERK1/2 in mouse skin. Ann NY Acad Sci 973 (2002) 396-401
205. Swerdlow R.H. Mitochondrial DNA-related mitochondrial dysfunction in neurodegenerative diseases. Arch Pathol Lab Med 126 (2002) 271-280
206. Swerdlow R.H. The neurodegenerative mitochondriopathies. J Alzheimers Dis June (2009) [Epub ahead of print]
207. Swerdlow R.H., Golbe L.I., Parks J.K., Cassarino D.S., Binder D.R., Grawey A.E., et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 75 (2000) 1681-1684
208. Swerdlow R.H., Parks J.K., Davis II J.N., Cassarino D.S., Trimmer P.A., Currie L.J., et al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 44 (1998) 873-881
209. Szeto H.H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 8 (2006) E277-E283
210. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47 (2000) 80-86
211. Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 106 (2009) 20021-20026
212. Takuma K., Yao J., Huang J., Xu H., Chen X., Luddy J., et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19 (2005) 597-598
213. Tasset I., Sanchez F., and Tunez I. The molecular bases of Huntington's disease: the role played by oxidative stress. Rev Neurol 49 (2009) 424-429
214. Trimmer P.A., Keeney P.M., Borland M.K., Simon F.A., Almeida J., Swerdlow R.H., et al. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol Dis 15 (2004) 29-39
215. Tsang A.H., and Chung K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 1792 (2009) 643-650
216. Turner C., Cooper J.M., and Schapira A.H. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord 22 (2007) 1715-1721
217. Vali S., Mythri R.B., Jagatha B., Padiadpu J., Ramanujan K.S., Andersen J.K., et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 149 (2007) 917-930
218. Valla J., Schneider L., Niedzielko T., Coon K.D., Caselli R., Sabbagh M.N., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6 (2006) 323-330
219. Varghese M., Pandey M., Samanta A., Gangopadhyay P.K., and Mohanakumar K.P. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. J Neurol Sci 279 (2009) 39-42
220. Wang H., Lim P.J., Karbowski M., and Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18 (2009) 737-752
221. Wang H.L., Chou A.H., Yeh T.H., Li A.H., Chen Y.L., Kuo Y.L., et al. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 28 (2007) 216-226
222. Wang X., Su B., Fujioka H., and Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 173 (2008) 470-482
223. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29 (2009) 9090-9103
224. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105 (2008) 19318-19323
225. Weber C.A., and Ernst M.E. Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 40 (2006) 935-938
226. Wiedemann F.R., Manfredi G., Mawrin C., Beal M.F., and Schon E.A. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 80 (2002) 616-625
227. Yang J.L., Weissman L., Bohr V.A., and Mattson M.P. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst) 7 (2008) 1110-1120
228. Yang X., Yang Y., Li G., Wang J., and Yang E.S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci 34 (2008) 165-171
229. Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 105 (2008) 7070-7075
230. Yao J., Taylor M., Davey F., Ren Y., Aiton J., Coote P., et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 35 (2007) 377-382
231. Yapa S.C. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health 106 (1992) 393-395
232. Yoshino H., Nakagawa-Hattori Y., Kondo T., and Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 4 (1992) 27-34
233. Young A.J., Johnson S., Steffens D.C., and Doraiswamy P.M. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr 12 (2007) 62-68
234. Yu J.T., Chang R.C., and Tan L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 89 November (3) (2009) 240-255
235. Zaidi S.M., and Banu N. Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Clin Chim Acta 340 (2004) 229-233
236. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61 (2004) 82-88
237. Zhang S.M., Hernan M.A., Chen H., Spiegelman D., Willett W.C., and Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59 (2002) 1161-1169
238. Zheng Z., Zhao H., Steinberg G.K., and Yenari M.A. Cellular and molecular events underlying ischemia-induced neuronal apoptosis. Drug News Perspect 16 (2003) 497-503
239. Zubenko G.S., and Sauer P. SOD-1 activity and platelet membrane fluidity in Alzheimer's disease. Biol Psychiatry 25 (1989) 671-678
240. Zullo S.J., Parks W.T., Chloupkova M., Wei B., Weiner H., Fenton W.A., et al. Stable transformation of CHO cells and human NARP cybrids confers oligomycin resistance (oli(r)) following transfer of a mitochondrial DNA-encoded oli(r) ATPase6 gene to the nuclear genome: a model system for mtDNA gene therapy. Rejuvenation Res 8 (2005) 18-28